Allergan to Present New Data on Extended Duration of IOP Control

Allergan plc, a leading global pharmaceutical company with more than 70 years of heritage in eye care, will present new data including a late-breaking abstract for Bimatoprost SR at the Annual Meeting of the American Glaucoma Society (AGS) to be held in San Francisco, California. The late-breaking abstract, to be presented for the first time during a podium session on Saturday, March 16, is the initial treatment duration analysis of Phase 3 clinical data for Bimatoprost SR, a first-in-class sustained-release, biodegradable implant being evaluated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Topline Phase 3 efficacy and safety results from the ongoing studies will also be presented at a congress later this year. Allergan anticipates submitting a New Drug Application (NDA) to the FDA in the second half of 2019.

“This first presentation showing the treatment duration from the Phase 3 studies confirms that Bimatoprost SR could represent a major paradigm shift in the management of glaucoma. Bimatoprost SR demonstrated an extended duration of effect in many patients, and the potential for most patients to need no additional treatment for one year after three administrations of the implant,” said Yehia Hashad, MD, Vice President and Global Head, Clinical Development, Eye Care, Allergan. “The development of Bimatoprost SR demonstrates our continued commitment to developing innovative therapies for glaucoma, a progressive disease that requires consistent IOP control to preserve vision for patients.” Allergan will present two abstracts, including one podium presentation (accepted as a late-breaking abstract) and one poster presentation (all noted in local Pacific Standard Time):

• AGS Poster Session (Friday, March 15, 7:00 AM – 5:00 PM): Logistic Regression Analysis of Baseline Patient Characteristics Predicting IOP Control Up to 24 Months After a Single Administration of Bimatoprost SR; Author: Ahmed IIK et al.
• AGS Podium Session (Saturday, March 16, 4:35 PM): Extended Duration of IOP Control with Intracameral Bimatoprost Sustained-Release Implant (Bim SR): Late-Breaking Phase 3 Clinical Trial Results; Author: Ahmed IIK et al; Time: 4:35 PM. – Medical Buyer Bureau